Our observations on lower levels of TF in relapsing than in remitting multiple sclerosis patients might also relate to negative feedback due to higher levels of TF pathway inhibitor (TFPI), which have been found in progressive phenotypes of multiple sclerosis compared with relapsing-remitting multiple sclerosis (56). Here, TF is linked to relapsing-remitting multiple sclerosis.